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Abstract
Background: Declining in clinical efficacy of artesunate-mefloquine combination has been documented in areas
along the eastern border (Thai-Cambodian) of Thailand. In the present study, the clinical efficacy of the three-day
combination regimen of artesunate-mefloquine as first-line treatment for acute uncomplicated falciparum malaria
in Thailand was monitored in an area along the western border (Thai-Myanmar) of the country.
Methods: A total of 150 Burmese patients (85 males and 65 females) aged between 16 and 50 years who were
attending the Mae Tao clinic, Mae-Sot, Tak Province, and presenting with symptomatic acute uncomplicated
Plasmodium falciparum malaria were included into the study. Patients were treated initially (day 0) with 4 mg/kg
body weight artesunate and 15 mg/kg body weight mefloquine. The dose regimen on day 2 was 4 mg/kg body
weight artesunate and 10 mg/kg body weight mefloquine. On day 3, artesunate at the dose of 4 mg/kg body
weight was given with 0.6 mg/kg body weight primaquine. Whole blood mefloquine and plasma artesunate and
dihydroartemisinin (active plasma metabolite of artesunate) concentrations following treatment were determined
by high performance liquid chromatography (HPLC) and liquid chromatography-mass spectrometry (LCMS),
respectively.
Results: Thirty-four cases had recrudescence during days 7 and 42. Five and 5 cases, respectively had reinfection
with P. falciparum and reappearance of Plasmodium vivax in their peripheral blood during follow-up. The Kaplan-
Meier estimate of the 42-and 28-day efficacy rates of this combination regimen were 72.58% (95% CI: 63.20-79.07%)
and 83.06 (95% CI 76.14-94.40%), respectively. Parasite clearance time (PCT) and fever clearance time (FCT) were
significantly prolonged in patients with treatment failure compared with those with sensitive response [median (95%
CI) values for PCT 32.0 (20.0-48.0) vs 24.0 (14.0-32.0) hr and FCT 30.0 (22.0-42.0) vs 26.0 (18.0-36.0) hr; p < 0.005]. Whole
blood mefloquine concentrations on days 1, 7 and 14 in patients with sensitive and recrudescence response were
comparable. Although plasma concentration of dihydroartemisinin at 1 hour of treatment was significantly lower in
patients with recrudescence compared with sensitive response [mean (95% CI) 456 (215-875) vs 525 (452-599) ng/ml;
p < 0.001], the proportion of patients with recrudescence who had relatively low (compared with the lower limit of
95% CI defined in the sensitive group) was significantly smaller than that of the sensitive group.
Conclusions: Although pharmacokinetic (ethnic-related) factors including resistance of P. falciparum to mefloquine
contribute to some treatment failure following treatment with a three-day combination regimen of artesunate-
mefloquine, results suggest that artesunate resistance may be emerging at the Thai-Myanmar border.
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Malaria remains a substantial public health problem in
several tropical areas. The development and spreading
of multidrug-resistant Plasmodium falciparum, particu-
larly the previous mainstay anti-malarial drug chloro-
quine, sulphadoxine-pyrimethamine and mefloquine is
further aggravating the situation [1]. This has compli-
cated efforts to control the disease, and can lead to
unnecessary mortality if ineffective drugs remain the
standard of care after drug-resistant strains become
established. To deal with the threat of resistance of
P. falciparum to monotherapies, combinations of anti-
malarials are now recommended by the World Health
Organization (WHO). Artemisinin-based combination
therapy (ACT) is widely promoted as a strategy to coun-
teract the increasing resistance of P. falciparum to anti-
malarials, as well as to prevent disease transmission and
reduce the risk of drug resistance [2].
In Thailand, where the most resistant parasites are
found, the National Malaria Control Programme has
successfully reduced malaria morbidity and mortality in
most areas of the country deploying vector control mea-
sures and a large network of malaria clinics delivering
free diagnosis and treatment [3]. The number of cases
has markedly decreased over the past few decades.
Malaria transmission is currently limited to displaced
persons and migrant workers in the forested and hilly
areas of the western and eastern border provinces of
Thailand along the Thai-Myanmar and Thai-Cambodian
borders. Thailand was the first country to use mono-
therapy of mefloquine for the treatment of uncompli-
cated malaria, but resistance to mefloquine developed
rapidly on both borders [4-6]. Mefloquine resistance led
to replacement by artesunate-mefloquine in Thailand in
1995, initially as a two-day combination regimen which
ensured better compliance than an extended three-day
r e g i m e no f2 5m g / k go fm e f l o q u i n ea n d1 2m g / k go f
artesunate [7]. This combination regimen has led to a
reduction in falciparum malaria incidence including
mefloquine resistance [8]. In 2007, the malaria
control programme of Thailand switched to a three-day
treatment course in accordance with WHO recommen-
dation. With the exception of the areas along the Thai-
Cambodian border, this combination regimen remains
effective throughout the country. Recent reports of high
failure rates associated with mefloquine-artesunate com-
bination, as well as in vitro drug-susceptibility data, sug-
gest the possibility of clinical artemisinin resistance
along the Thai-Cambodian border [9,10]. A considerable
proportion of the malaria cases in Thailand is due to
transmission occurring across both Thai-Cambodian
and Thai-Myanmar borders. Substantial exchange of
parasites occurs across these borders and it would,
therefore, be expected that t h ep a r a s i t ep o p u l a t i o n si n
both border areas are similar.
In the present study, the clinical efficacy of the three-
day combination regimen of artesunate-mefloquine was
investigated in a total of 150 Burmese patients who
r e s i d e di na na r e aa l o n gt h eT h a i - M y a n m a rb o r d e r .
Resistance of P. falciparum strains was confirmed by the
adequacy of whole blood mefloquine and plasma artesu-
nate/dihydroartemisinin concentrations following
treatment.
Methods
Study site and patients
The study was conducted at Mae Tao clinic for migrant
workers, Tak Province during March 2008-February 2009.
Malaria is a serious imported medical problem in this area
with a low and stable disease transmission with two seaso-
nal peaks and forest-related during May-August and
November-January of each year. Anopheles minimus and
Anopheles dirus are the principal vectors. P. falciparum
and Plasmodium vivax are the two predominant species
with the incidence of 1:1, Plasmodium malariae is occa-
sionally found and Plasmodium ovale is rare. All age
groups are affected and nearly all the P. falciparum infec-
tions are symptomatic [11].
The study was approved by the Ethics Committee of
the Ministry of Public Health of Thailand. A total of
150 Burmese patients aged above 15 years who pre-
sented with typical symptoms of malaria and had a
blood smear positive for P. falciparum were included
into the study. Inclusion criteria for enrolment in the
study were according to the WHO protocol for areas
with low to moderate malaria transmission [12]: axillary
temperature ≥37.5°C or recent history of fever; a slide-
confirmed P. falciparum mono-infection with a parasite
density 1,000-100,000 asexual parasites/μl. Patients with
signs of severe or complicated malaria [13], febrile dis-
eases other than malaria, presence of severe malnutri-
tion, history of hypersensitivity reactions to any of the
study drugs, and pregnant or breast-feeding women
were not included. Written informed consents were
obtained from all patients before study participation.
Treatment, sample collection and follow-up
Prior to treatment (day 0), blood sample (3 ml) was col-
lected from each patient for determination of baseline
anti-malarial drug concentrations (mefloquine, artesunate
and dihydroartemisinin). Patients were treated with a
three-day combination regimen of artesunate and meflo-
quine. The initial dose of 4 mg/kg body weight artesunate
(200 mg, 4 tablets of 50 mg artesunate, Atlantic Pharma-
ceutical Company, Thailand) and 15 mg/kg body weight
mefloquine (750 mg, 3 tablets of 250 mg mefloquine;
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on the first day (day 0). The dose regimen on day 2 was
4 mg/kg body weight artesunate (200 mg, 4 tablets of
50 mg artesunate) and 10 mg/kg body weight mefloquine
(500 mg, 2 tablets of 250 mg mefloquine). On day 3, arte-
sunate at the dose of 4 mg/kg body weight was given with
0.6 mg/kg body weight primaquine (2 tablets of 15 mg
primaquine; Government Pharmaceutical Organization of
Thailand). All doses were given under supervision and
patients were observed for 30 minutes. If patient vomited
within 30 minute, the drug dosages were repeated. When
necessary, symptomatic treatment with antipyretic parace-
tamol, and anti-emetic dimenhydrinate was administered.
Patients were admitted to the clinic during the three-
day course of treatment or until signs and synptoms of
malaria disappeared. Blood samples were collected into
sodium heparinized tubes at various time points after
the first dose from different sub-groups of patients for
determination of mefloquine (1 ml whole blood) and
artesunate/dihydroartemisinin (1 ml plasma) levels. This
was part of the population pharmacokinetics/pharmaco-
dynamics study (to be described elsewhere). Plasma
samples for determination of artesunate and dihydroar-
temisinin were separated within 30 min after collection
through centrifugation at 1,200 × g for 15 min and
stored at -180°C in a liquid nitrogen tank until analysis.
Whole blood samples for mefloquine were immediately
stored at -20°C until analysis.
Patients were requested to return for follow-up on days
7, 14, 21, 28 and 42 or at any time if fever or symptoms
suggestive of malaria developed. At each visit, a parasite
count was performed (Giemsa-stain), and a detailed
questionnaire for general symptoms was recorded.
Malaria blood smears were obtained on enrolment and
thereafter, twice daily until two consecutive slides were
confirmed to be negative, as well as at every follow-up
visit. Thick films were screened for 200 oil-immersion
fields before declaring a slide negative. Asexual parasites
and gametocytes were separately counted against 200
WBCs; if the parasite density was too numerous to count
on the thick film, the number of parasites per 2,000 RBCs
on the thin film was counted.
Patients failing to respond to the three-day regimen
of artesunate-mefloquine were treated with the sec-
ond-line treatment for uncomplicated falciparum
malaria (quinine plus doxycycline given for 7 days).
Those who developed P. vivax malaria in their periph-
eral blood during the follow-up periods were treated
with 300 mg (base) of chloroquine to suppress symp-
toms and a full course of treatment was given at the
e n do ft h es t u d yp e r i o d( c h l o r o q u i n e1 , 5 0 0m gg i v e n
over 48 hours, followed by 15 mg (base) of primaquine
daily for 14 days).
Efficacy assessment
T h ec l i n i c a lo u t c o m eo fa3d a yc o u r s eo fa r t e s u n a t e -
mefloquine was evaluated in the group of patients who
completed the 42 day follow-up period. The classifica-
tion of the therapeutic outcome was according to the
WHO protocol [12] as ‘Adequate Clinical and Parasito-
logical Response (ACPR)’, ‘Early Treatment Failure
(ETF)’ and ‘Late Treatment Failure (LTF)’,w h i c hw a s
further classified as ‘Late Parasitological Failure’ (LPF)
or ‘Late Clinical Failure (LCF)’. The primary end point
was the 42-day cure rate and was defined as proportion
of patients with ACPR after 42 days of follow-up.
Secondary endpoint parameters included parasite clear-
ance time (PCT), proportions of patients with clearance
of parasitaemia by 24 (PCT24 hr)a n d4 8( P C T 48 hr)
hours, fever clearance time (FCT), proportions of
patients with clearance of fever by 24 (FCT24 hr)a n d4 8
(FCT48 hr) hours. PCT was defined as the time until the
first series of negative smears occurred and FCT as the
time from start of treatment until the axillary tempera-
ture decreased to below 37.5°C and remained below this
temperature for the next 48 hours.
Reinfections
In order to distinguish between reinfection and recru-
descence, P. falciparum genotyping was performed on
paired samples of P. falciparum DNA. Blood spots from
each patient were collected on filterpaper (3 MM;
Whatman, Springfield Mill, UK) and parasite variants of
pre-treatment and post-treatment sample pairs were
identified by using nested PCR amplification of 3 poly-
morphic genes for merozoite surface protein 1 (msp1),
msp2, and glutamate-rich protein [14].
Drug analysis
Concentrations of mefloquine in whole blood were mea-
sured by high performance liquid chromatography with
UV-detection (HPLC-UV) according to the method of
Karbwang [15], with quantification limit of 2 ng/ml.
Plasma concentrations of artesunate and its active metabo-
lite dihydroartemisinin were measured by liquid chrolato-
graphy mass-pectrometry (LCMS) according to the
method of Thuy [16], with quantification limit of 2 ng/ml.
Data analysis
Kaplan-Meier analysis was performed to calculate the
proportion of parasitemic patients at each follow-up
visit (days 7, 14, 21, 28, 35 and 42). Mean (95% CI)
values were used to present the data which were nor-
mally-distributed continuous variables and statistical
analysis for comparison was performed using analysis of
variance (ANOVA), student t-test, or paired t-test,
where appropriate. Median (95% CI) values were used
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continuous variables and statistical analysis for compari-
son was performed using Kruskal Wallis, Mann-Whitney
U test or Wilcoxon Signed Rank test, where appropriate.
Difference in proportion was investigated using the
Chi-squared test. Statistical significance was set at
a = 0.05 for all tests.
Results
Clinical efficacy
A total of 150 Burmese patients (85 males, 65 females)
aged between 16 and 50 years with acute uncomplicated
falciparum malaria received treatment with the first-line
three-day artesunate-mefloquine combination. The treat-
ment regimen was well tolerated; only 17 and 21 cases
had nausea and headache, respectively. One hundred and
thirty-two patients were evaluable for primary endpoint;
18 cases were lost to follow up during days 7 and 35.
Among the 132 evaluable cases, 39 cases developed LTF,
all of which were classified as LPF (recrudescence
between day 7 and day 42). The median time until
reemergence of parasites in the peripheral blood was
28.0 days (95% CI 7.0-42.0 days). Molecular analysis
s u g g e s t e dt h a tf i v ep a t i e n t s had acquired a reinfection
with P. falciparum during the 42 days follow-up (days 23,
24, 28, 35 and 42). Most treatment failures (11 cases)
occurred during the fourth week of follow up. Five cases
had reappearance of P. vivax in their peripheral blood on
days 35 (2 cases) and 42 (3 cases). The probability esti-
mate for ACPR at day 42 (42-day cure rate) and day 28
(28-day cure rate) in Kaplan-Meier analysis were 72.58%
(90/124: 95% CI: 63.20-79.07%) and 83.06 (104/124: 95%
CI 76.14-94.40%), respectively (Figure 1).
Patients with recrudescence (confirmed by PCR) and
sensitive responses were well matched in regard to sex,
age, weight, height, and parasite density on enrollment
(Table 1). The PCT and FCT were significantly pro-
longed in patients with recrudescence compared with
those with sensitive response [median (95% CI) values
for PCT 32.0 (20.0-48.0) vs 24.0 (14.0-32.0) hr; and FCT
30.0 (22.0-42.0) vs 26.0 (18.0-36.0) hr]. In addition, the
proportions of patients who had parasitaemia (PCT24 hr)
and fever (FCT24 hr) cleared within 24 hours were signif-
icantly higher in the group with sensitive response
(Table 1).
Drug concentrations
Whole blood mefloquine concentrations on days 0 (pre-
treatment), 1, 7 and 14 of treatment are summarized in
T a b l e2a n dF i g u r e2a n dp l a s m aa r t e s u n a t ea n dd i h y -
droartemisinin at 0 (pre-treatment) 1 and 6 hour after
the first dose are summarized in Table 3 and Figure 3.
Baseline mefloquine concentrations were detected in 15
(11.36%) cases (11 and 4 cases in the group with sensitive
and recrudescence response, respectively) with median
(95% CI) of 0 (0-220) ng/ml. No measurable baseline
artesunate or dihydroartemisinin was found. Whole
blood mefloquine concentrations tended to be lower
on days 1, 7, 14 and 21 of treatment in patients with
recrudescence response (Table 2). However, due to large
Figure 1 Kaplan-Meier curve for a 42-day follow-up in 124 patients after treatment with a three-day combination regimen of
artesunate-mefloquine.
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reached. Patients who had reappearance of parasitaemia
on day 7 (1 case) or day 42 (5 cases) had similar meflo-
quine concentrations on days 1, 7 and 14. Nevertheless,
the proportion of patients in the recrudescence group
who had mefloquine concentrations on days 1, 7 and 14
lower than the lower limit of 95% CI for median concen-
trations defined in the sensitive group (1,377, 738 and
442 ng/ml for days 1, 7 and 14, respectively) was signifi-
cantly larger than the sensitive group [5 (41.7%) vs 9
(25%), 3 (33.3%) vs 2 (9%) and 5 (50%) vs 5 (23.8%) cases
for concentrations on day 1, 7 and 14, respectively]
(Figure 2). Plasma aretsunate concentrations at 1 and 6
hours after the first dose were comparable between the
group with recrudescence and sensitive response. On the
other hand, dihydroartemisinin concentrations at 1 hour
of treatment was significantly lower in patients with
recrudescence response [mean (95% CI) 456 (215-875) vs
525 (452-599) ng/ml]. For both artesunate and dihy-
droartemisinin, the proportions of patients in the recru-
descence group who had the concentrations at 1 hour
after the first dose lower than the lower limit of 95% CI
for median concentrations defined in the sensitive group
(312 and 445 ng/ml for artesunate and dihydroartemisi-
nin, respectively) was significantly smaller than the sensi-
tive group [8 (26.6%) vs 26 (40%) and 10 (33.3%) vs 30
(46.1%) for artesunate and dihydroartemisinin, respec-
tively] (Figure 3). Among the 34 cases with recrudes-
cence, 12 had adequate blood/plasma concentrations of
both mefloquine and dihydroartemisinin. Inadequacy of
mefloquine and dihydroartemisinin concentrations was
observed in 13 and 10 cases with recrudescence, respec-
tively. Inadequate concentrations of both drugs was
found in one case.
Table 1 Summary of cases included in the study and clinical response
Sensitive response Recrudescence response
N 90 34
Age (yr) 25.0 (18-50) 25.0 (16.0-45.0)
Sex (n: male, female) 47, 43 15, 19
Body weight (kg) 55.0 (39.0-72.0) 52.0 (44.0-73.5)
Admission parasitemia (/ml) 5,232(1,260-84,000) 6,002(2,450-34,300)
Parasitemia on the day of recrudescence (/ml) - 1,030(120-3,300)
Day of recrudescence (days) - 28.0 (7.0-42.0)
PCT (hr) 24.0(14.0-32.0) 32.0(20.0-48.0)
a
PCT24 hr (hr: n, %) 56, 62.2
b 6, 17.6
PCT48 hr (hr: n, %) 90, 100 34, 100
FCT (hr) 26.0(18.0-36.0) 30.0(22.0-42.0)
c
FCT24 hr (hr: n, %) 37, 41.1
d 7, 20.5
FCT48 hr (hr: n, %) 90, 100 34, 100
Data are presented as median (95% CI) or proportion (n, %).
a= Statistically significantly longer than patients with sensitive response (Mann Whitney U-test, p < 0.005).
b= Statistically significantly higher than patients with recrudescence response (Chi-square test, p < 0.01).
c= Statistically significantly longer than patients with sensitive response (Mann Whitney U-test, p < 0.005).
d= Statistically significantly higher than patients with recrudescence response (Chi-square test, p < 0.01).
Table 2 Whole blood concentrations of mefloquine on Day-0 (pre-treatment), days 7, 14, 21, 28, 35 and 42 of
treatment in patients with sensitive response and recrudescence
Day of treatment Sensitive response Recrudescence response
N Mean (95%CI)* or Median (95% CI)** N Mean (95%CI)* or Median (95% CI)**
Day 0** 90 0 (0-1,714) 36 0 (0-92)
Day 1* 36 1,411 (1,216-1,605) 12 1,345 (1,067-1,624)
Day 7* 22 1,055 (806-1,304) 9 754 (541-968)
Day 14* 21 659 (426-893) 10 421 (181-660)
Day 21* 15 416 (258-575) 11 359 (230-488)
Day 28* 13 233 (158-307) 8 288 (146-329)
Day 35* 12 145 (96-195) 6 179 (41-317)
Day 42** 19 19 (5-163) 9 13 (0-49)
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and recrudescence (R) response. Dot lines represent the lower and upper level of 95% CI defined in the sensitive group.
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An artesunate-mefloquine combination (with meflo-
quine doses varying from 750 to 1,250 mg depending on
endemic areas) given in three days has become the first-
line treatment for falciparum malaria in Thailand since
2005 with satisfactory clinical efficacy and tolerability. In
the present study however, it is noted for an unexpect-
edly high failure rate for this three-day combination for
treatment of uncomplicated falciparum malaria in the
area along the Thai-Myanmar border. The cure rates at
28 and 42 days, calculated by Kaplan-Meier survival
analysis and PCR correction for re-infection, were 83.06
and 72.58%, respectively. It is noted that reappearance
of parasitaemia occurred as early as 7 days till 42 days
after the first dose. In addition, there was a small but
significant delay of parasite clearance in the group with
recrudescence response [median (range) PCT 32.0 (20.0-
48.0) hours] compared to the sensitive group [24.0
(14.0-32.0) hours]. Only 6 (17.6%) and 7 (20.5%) patients
with recrudescence response respectively, had parasitae-
mia (PCT24 hr)a n df e v e r( F C T 24 hr) cleared within
24 hours. The efficacy of this combination was markedly
dropped when compared with our recent investigation
during 2008-2009 with the same regimen in the same
area, where a 42-day cure rate of 99.2% was obtained
[17]. In other studies conducted in the same area
reported during 1997-2003, a 28 or 42 day cure rates
[18-20] for artesunate-mefloquine combination were
also approaching 100%. In the areas of Thai-Cambodian
border (Ranong, Chantaburi Provinces) with highly
mefloquine resistance except Trad Province (78.6%),
cure rates were greater than 90% [9]. The high failure
rate observed in the present study was not due to com-
pliance factor since all patients were admitted in the
clinic during the three-day course of treatment. Meflo-
quine baseline level ranging from 9-300 ng/ml detected
in about 11.3% would imply previous treatment with
mefloquine for the previous/current malaria episode. In
our previous study, compliance with this three-day com-
bination regimen conducted in malaria clinics under the
Malaria Control Program of Thailand was also high
(96.3%) and baseline mefloquine levels were observed in
24% [17].
‘Genuine resistance’ of treatment failure cases was con-
firmed by monitoring for the adequacy of whole blood
mefloquine and plasma artesunate/dihydroartemisinin
concentrations. Mefloquine concentrations on days 1, 7
and 14 of treatment in patients with recrudescence
response tended to be lower than those with sensitive
response and with larger proportion of cases with the con-
centrations (on days 1, 7 and 14) lower than the lower
limit of 95% CI defined in the sensitive group. Blood con-
centrations of mefloquine on day 1 of treatment has been
reported to be an important determinant of successful
treatment [21]. On the other hand, although dihydroarte-
misinin concentrations were significantly lower in patients
with recrudescence, the smaller proportion of patients in
the recrudescence group had the concentrations at 1 hour
of treatment of both artesunate and dihydroartemisinin
lower than the threshold levels compared with the sensi-
tive group (8 vs 26% and 10 vs 30%, respectively). Dihy-
droartemisinin is the active plasma metabolite of
artesunate, which has a longer half-life (1-2 hours) with
potency 2-4 times greater than the parent drug [22]. This
suggests that despite the relatively low dihydroartemisinin
concentration at 1 hour (< 445 ng/ml) in about 33%
(10 cases) of patients with recrudescence response, they
were in most cases adequately kill P. falciparum isolates in
this area. There has been no defined threshold levels of
artesunate/dihydroartemisinin for treatment of falciparum
malaria but it is noted however that artesunate concentra-
tion (at 1 hour) of as low as 120 ng/ml was adequate in
two patients with sensitive response, while dihydroartemi-
sinin concentration (at 1 hour) of as high as 1,250 ng/ml
was inadequate in one case with recrudescence. The later
had also confirmed adequate mefloquine concentrations
Table 3 Plasma concentrations of artesunate and dihydroartemisinin on day-0 (pre-treatment) and at 1 and 6 hours
after treatment in patients with sensitive response and recrudescence
Drug/Day of treatment Sensitive response Recrudescence response
N Mean (95%CI)* or Median (95% CI)** N Mean (95%CI)* or Median (95% CI)**
Artesunate:
Day 0** 90 0 35 0
Hour 1* 65 344 (312-375) 30 323 (282-364)
Hour 6** 64 1 (0-1,253) 30 0 (0-12)
Dihydroartemisinin:
Day 0** 90 0 (0-10) 35 0
Hour 1* 65 525 (452-599) 30 456 (215-875)
a
Hour 6** 64 98 (13-220) 30 100 (0-220)
a = Statistically significantly lower than patients with sensitive response (student t-test; p < 0.001).
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Page 7 of 10Figure 3 Plasma artesunate (a) and dihydroartemisinin (b) concentrations at 1 hour of the first dose in day 1 in patients with
sensitive (S) and recrudescence (R) response. Dot lines represent the lower and upper level of 95% CI defined in the sensitive group.
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firmed adequacy of whole blood/plasma concentrations of
both mefloquine and dihydroartemisinin, in adequacy of
the concentrations of mefloquine alone, dihydroartemisi-
nin alone and both contributed to 13, 10 and one cases
with treatment failure, respectively. None of the treatment
failure vomited the doses of mefloquine or artesunate. It
was reported that patients from Tak Province experiences
a lower frequency of nausea and vomiting than other
groups [9].
Results of clinical efficacy together with drug concentra-
tion profiles may suggest the possibility of contribution of
pharmacokinetic factors as well as mefloquine and artesu-
nate/dihydroartemisinin resistance to the observed high
failure rate of the current three-day combination regimen.
With the absence of in vitro sensitivity data of individual
parasite isolate, it is difficult to clearly define whether
reduced clinical efficacy of the combination is due to
which of each partner drug. It is noted however that
mefloquine concentration profiles in this patient popula-
tion (Burmese) appear lower (by about 30%) than our pre-
vious reports in Thai patients following the same dose of
mefloquine [17,23]. The relatively low mefloquine concen-
trations in the recrudescence cases may be due to variabil-
ity in pharmacokinetics and the levels were no longer
adequate once the level of mefloquine resistance is aggra-
vating. Furthermore, it also appears possible that artesu-
nate resistance is beginning to emerge in this area on a
background of pre-existing mefloquine resistance. Solely
mefloquine resistance should not significantly affect
the parasite clearance time following treatment with arte-
sunate-mefloquine combination. However, with a good
malaria control in this area, the contribution of low immu-
nity to poor clinical response cannot be excluded. Meflo-
quine was used as mono-therapy for treatment of acute
uncomplicated falciparum in this area long before the
introduction of the combination regimen and thus meflo-
quine resistance in this area had already reached a level
too extreme to protect the development and spread of
artesunate resistance. The high proportion of patients with
baseline mefloquine concentrations points to the high
selective drug pressure in this area. The dramatic drop in
clinical efficacy of the three-day artesunate-mefloquine
combination after 13 years continuous deployment in this
area is alarming and is of concern as that has occurred in
the Thai-Cambodian border and containment measures
are urgently needed. In the Thai-Cambodian border, resis-
tance was characterized by a markedly prolonged time to
parasite clearance, without corresponding reductions on
conventional in vitro susceptibility testing, pharmacoki-
netic or other host factors [24]. Analysis of in vitro sus-
ceptibility of the parasite isolates (baseline and the day of
recrudescence) together with candidate molecular markers
of resistance (amplification and SNPs of pfmdr1 and
pfatp6) are under way, to clearly define, with support of
drug concentration data, if the reduced artesunate-meflo-
quine efficacy observed is really due to a true decline in
artesunate sensitivity or a further progression of meflo-
quine resistance or both [25,26]. Of particular concern
is the increased transmissibility of these tolerant parasites.
Close monitoring of the in vitro susceptibility of P. falci-
parum to mefloquine and artesunate/dihydroartemisinin
in this area, and in particular vigilance to detect early
emergence of higher levels of artemisinin resistance is
required
Conclusions
T h ep r e s e n ts t u d yw a st h ef i r s to b s e r v a t i o no fam a r k e d
decline in clinical efficacy of a three-day artesunate-
mefloquine regimen in the area along the Thai-Myanmar
border. Although pharmacokinetic (ethnic-related)
factors including resistance of the parasite to mefloquine
mainly contribute to some treatment failure, results sug-
gest that artesunate resistance may be emerging at the
Thai-Myanmar border.
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